So far, clinically approved liposome drug formulations do not include specific active-targeting strategies (Doxil®/CaelyxTM, DaunoXome®, Myocet®, Marqibo®, Onivyde®, VyxeosTM); however, a doxorubicin-loaded immunoliposome targeted with Cetuximab (mAb epidermal growth factor receptor (EGFR) inhibitor) Fab fragments is in Phase II clinical trials for the treatment of advanced triple-negative EGFR-positive breast cancer (Clinical trial NCT02833766). Here, EGFR is linked to breast cancer.